A Pathological Collagen-Targeting Nanozyme Chip for Ultrasensitive Quantification of Collagen in Body Fluids.

Pathological collagen emerges as a critical biomarker in the progression of tumors, fibrotic disorders, and osteoarthritis. The precise quantification of pathological collagen holds critical diagnostic value, offering a noninvasive approach for early detection of collagen-associated disorders. A pathological collagen targeting nanozyme biochip (PCC) has been constructed for the first time to ultrasensitively quantify pathological collagen in body fluids. The PCC biosensor consists of a high-affinity pathological collagen targeting nanozyme (Pacotzyme) and a capture surface for efficient enrichment of unbound Pacotzyme. The PCC has been demonstrated to quantitatively analyze pathological collagen across a wide concentration range from 0.1 to 10000 ng/mL, with an LOD as low as 15 pg/mL. PCC demonstrates robust and precise performance in intricate biological environments characterized by elevated protein content, high ionic strength, and increased glucose levels. Moreover, PCC exhibits consistent and reliable functionality in diverse body fluids, including serum, urine, saliva, and synovial fluid. Notably, PCC chips have been successfully applied to detect cancer, fibrosis, and osteoarthritis by quantifying pathological collagen in body fluids. The specific nanozyme biosensor offers a promising diagnostic tool for the early screening and noninvasive diagnosis of collagen-related diseases.